



TIRZEPATIDE

Dual GIP/GLP-1 agonist – an approved drug with a compounding complication

Tirzepatide has among the strongest clinical evidence of any compound in this range, backed by the completed SURPASS and SURMOUNT phase III programmes. It also has the most complicated compounding position, and that is the part most buyers have not been told about.

● In Plain English

Tirzepatide activates two gut hormone receptors at once. GLP-1 reduces appetite and slows stomach emptying; GIP appears to improve how well GLP-1 works and helps with how the body handles fat and glucose. Hitting both is why it outperformed the single-target drugs that came before it, and the trial results behind that claim are real, large and published.

What people use it for. Weight loss and blood sugar control. Alongside retatrutide, it is the most effective option in the metabolic category.

What to know before you buy. The clinical evidence here is genuinely excellent – large, randomised, published trials, not case reports. The complication is legal rather than scientific. During the 2022-2024 shortage, compounding pharmacies could lawfully make copies of tirzepatide. FDA declared that shortage over in December 2024, which removed that basis. Anyone buying or selling compounded tirzepatide should understand that the ground shifted. Titrate slowly for the same gastrointestinal reasons as retatrutide.

● What It's Used For

GOAL	WHAT THAT RESTS ON
Weight loss	SURMOUNT-1 reported ~20.9% mean weight reduction at 72 weeks – large, randomised, placebo-controlled and published
Blood sugar control	The SURPASS programme established glycaemic efficacy in type 2 diabetes
Appetite control	GLP-1 receptor activation slows gastric emptying and reduces appetite
Dual mechanism	Adding GIP is why it outperformed the single-target drugs before it

The left column lists goals people commonly pursue with this compound; the right column states what that rests on. These are described uses and research findings, not proven outcomes or treatment claims. Individual results vary and no outcome is promised.

● Pricing & Sizes

PRICING

10mg vial	\$60
-----------	------

30mg vial	\$130
-----------	-------

60mg vial	\$170
-----------	-------

Bulk pricing: 2-3 vials -5% | 4-6 vials -10% | 7-9 vials -15% | 10+ vials -20%

Ships sealed and lyophilized — stable for years at room temperature, reconstitute before use, or ask and it will be reconstituted free at the volume shown below. **Free shipping on every order, no minimum.** Third-party COA available for every batch — HPLC purity and mass spec verification.

Reconstitution — bacteriostatic water: 10mg vial at 2mL = 5mg/mL, so 10 units on a 100-unit syringe draws 0.5mg; 30mg vial at 3mL = 10mg/mL, so 10 units on a 100-unit syringe draws 1mg; 60mg vial at 3mL = 20mg/mL, so 10 units on a 100-unit syringe draws 2mg. Concentrations are arithmetic from vial content and diluent volume, not a dosing recommendation.

● At a Glance

CLASS	Dual agonist at GIP and GLP-1 receptors
FDA STATUS	Approved — as Mounjaro for type 2 diabetes and Zepbound for chronic weight management
TRIAL EVIDENCE	SURMOUNT-1 reported mean weight reduction of approximately 20.9% at 72 weeks on the highest dose in adults with obesity
COMPOUNDING	FDA declared the tirzepatide shortage resolved in December 2024 , which ended the shortage-based basis for compounding copies under 503A and 503B
PRACTICAL MEANING	Compounded tirzepatide no longer has the legal footing it had during the shortage period. This is separate from, and unaffected by, the July 2026 PCAC process
FORMAT	10mg, 30mg and 60mg vials

~20.9%

WEIGHT LOSS, SURMOUNT-1

2

RECEPTOR TARGETS

FDA

APPROVED (BRAND)

Dec 2024

SHORTAGE RESOLVED

REGULATORY STATUS — THIS ONE IS DIFFERENT

Tirzepatide is an **FDA-approved drug**, sold as Mounjaro and Zepbound. Because an approved product exists, the rules governing compounded versions are different from every other compound in this range. During the 2022-2024 shortage, compounders could lawfully prepare copies; FDA declared that shortage **resolved in December 2024**, removing that basis. Compounded tirzepatide is therefore in a materially different and more exposed position than it was, and this has nothing to do with the July 2026 PCAC hearing, which did not consider tirzepatide.

● What the Trials Show

This is one of the few compounds here where the evidence is unambiguous. The SURPASS programme established glycaemic efficacy in type 2 diabetes; the SURMOUNT programme established weight reduction in obesity. SURMOUNT-1 reported roughly 20.9% mean weight reduction at 72 weeks on the top dose — figures that came from large, randomised, placebo-controlled trials with published results, not case series.

Adverse events were predominantly gastrointestinal and dose-related: nausea, diarrhoea, vomiting and constipation, concentrated during dose escalation. The gradual titration schedules used in the trials exist specifically to manage this, and compressing them is the most common practical error.

● What Research-Grade Material Is and Is Not

The trial results above were produced with the approved pharmaceutical product, manufactured under cGMP with full identity, purity and potency controls and dispensed with prescribing information. Research-grade tirzepatide is not that product and inherits none of those controls. The efficacy data belongs to the approved drug; it does not automatically transfer to material from an unregulated supply chain.

This distinction matters more for tirzepatide than for the unapproved compounds in this range, precisely because an approved comparator exists and the gap between the two is measurable.

THE BOTTOM LINE

The strongest efficacy evidence in this range by a wide margin, attached to the most complicated legal position. The science is settled; the compounding pathway narrowed considerably when FDA declared the shortage resolved in December 2024. Anyone buying or selling this should understand that change.

● Also in the Range

Compare with **Retatrutide**, which reported larger reductions in phase II and adds a third receptor target, but has not completed phase III and is not approved anywhere.

Research use only. Products referenced in this document are supplied for laboratory and research purposes only and are **not for human or veterinary consumption**, not for diagnostic use, and not for use in food or cosmetics. They are not sold as drugs, dietary supplements or medical devices. **Not medical advice.** This document summarises publicly available research and is provided for informational and educational purposes only. It is not medical advice, not a diagnosis, not a treatment recommendation, and not an offer or promise to treat, cure, mitigate or prevent any disease or condition. Nothing here should be relied upon in place of advice from a qualified, licensed healthcare professional, and you should consult one before making any health decision. **On the statements made here.** Descriptions of research findings summarise what published studies have reported. They are not claims of safety or efficacy, and they should not be read as representing that any outcome will occur. Where research is preclinical (cell or animal), findings may not translate to humans. Individual results vary, and no particular result is promised or implied. Unless expressly stated otherwise, compounds described here are **not approved by the FDA** for any indication. **Regulatory information.** Regulatory positions described are current as of the date of this document and are subject to change without notice; verify current status independently before relying on it. **Buyer responsibility.** Purchasers are responsible for determining the lawfulness of purchase, possession and use in their jurisdiction. **No warranty.** This information is provided "as is" without warranty of any kind, express or implied. To the fullest extent permitted by law, no liability is accepted for any loss or damage arising from reliance on it. **Pricing.** Prices shown are current as of the date of this document, are subject to change without notice, and do not constitute a binding offer. **Sources:** SURMOUNT-1 and SURPASS trial programmes; FDA drug shortage database, tirzepatide shortage resolution December 2024; FDA prescribing information for Mounjaro and Zepbound.